by Steven Grossman | Sep 30, 2025 | Short Takes and Updates
I have experienced numerous shutdowns and shutdown threats. Sadly, they have become a familiar part of my DC life. Most often, there is a last-minute deal–whether a 48-hour Continuing Resolution (CR), a week-long CR, or a 6-week CR. No one expects a last-minute...
by Steven Grossman | Sep 26, 2025 | Short Takes and Updates
Flooding the zone has proven to be an extremely effective strategy for the Trump administration. Every day, there are dramatic headlines that I need to ignore to stay focused on the topic that matters most to me, namely the FDA. The flood has been unrelenting. The FDA...
by Steven Grossman | Sep 20, 2025 | Short Takes and Updates
First published in MedPage Today in its Second Opinions columnsOpen minds and expert input are crucial for policymaking….Based on my personal experience, dating back more than 40 years and spanning the administrations of 12 prior HHS secretaries, I can say that Robert...
by Steven Grossman | Sep 17, 2025 | Short Takes and Updates
To many of us, advisory committee meetings are emblematic of an FDA that listens, is open to diverse viewpoints, and is willing to change direction when other views prove compelling. FDA never yields the authority to decide. Yet, agency decisions about high-profile...
by Steven Grossman | Sep 5, 2025 | Short Takes and Updates
FDA Matters doesn’t cover the news….we provide analysis of what’s behind the newsThis week: My Comment on Secretary Kennedy’s September 4 Appearance Before the Senate Finance CommitteeMAHA Strategy Plan Likely to Be Released Week of September 8.MAHA...
by Steven Grossman | Aug 28, 2025 | Short Takes and Updates
For much of the past 20 years, my primary professional responsibility has been to impress upon lawmakers, the media, and stakeholders that FDA’s value far exceeds its budget. Sometimes, I would emphasize the economics — FDA oversees goods and services that total...
